Medical innovator Polyphotonix has struck a deal with global diabetes equipment provider embecta to supply its sleep mask technology in the UK and Ireland.
It is hoped the partnership, initially with the UK arm of US-based embecta, means the County Durham-developed Noctura 400 Sleep Mask will find more uptake among healthcare professionals. Polyphotonix's mask is worn overnight and emits light at a particular wavelength into the wearer's eyes, treating diabetic retinopathy - a condition which causes high blood sugar levels to damage the back of the eye and can lead to blindness.
Research has shown the technology's effectiveness in improving and stabilising diabetic eye disease by providing an early stage, non-invasive alternative to current treatments such as eye injections. Last year the firm received $10m from investors Prevail Partners LLC as part of a Series A investment.
